Antimicrobial Resistance (AMR)
AMR is an emerging and devastating global health problem caused directly by over-use of antibiotics. AMR jeopardizes our ability to perform many life-saving procedures such as major surgery and cancer therapy
In 2020, approximately 700 000 people died from antibiotic resistant infections, by 2050 as many as 10 million deaths are forecast if the situation is not changed.

AdjuTec addresses this global problem by developing adjuvant technologies that inhibits key bacterial resistance mechanisms, restoring antibiotic efficacy against life-threatening, multidrug resistant bacterial infections.
Carbapenems e.g. meropenem, are antibiotics reserved for life-threatening infections. Carbapenemases are enzymes produced by bacteria that destroy carbapenems, conferring resistance to potentially deadly infections.

AdjuTec develops products to inhibit the two main carbapenemase families, serine β-lactamases (SBL) and metallo-β-lactamases (MBL) also called beta-lactamase-inhibitors (BLI).
Tuberculosis (TB) is today the top infectious killer world-wide with 1.8mill fatalities out of 10mill diagnosed patients in 2019. TB is an opportunistic mycobacterium residing dormant in human cells that may develop into potentially deadly lung infections at a given point. Multidrug resistant TB is practically incurable by standard first-line treatment, and an increasing number of infections are becoming resistant to all available treatments.

AdjuTec addresses this global problem by developing a class of compounds inhibiting the DNA function of resistant TB bacteria
In 2020, approximately 700 000 people died from antibiotic resistant infections, by 2050 as many as 10 million deaths are forecast if the situation is not changed.

AdjuTec addresses this global problem by developing adjuvant technologies that inhibits key bacterial resistance mechanisms, restoring antibiotic efficacy against life-threatening, multidrug resistant bacterial infections.
Carbapenems e.g. meropenem, are antibiotics reserved for life-threatening infections. Carbapenemases are enzymes produced by bacteria that destroy carbapenems, conferring resistance to potentially deadly infections.

AdjuTec develops products to inhibit the two main carbapenemase families, serine β-lactamases (SBL) and metallo-β-lactamases (MBL) also called beta-lactamase-inhibitors (BLI).
Tuberculosis (TB) is today the top infectious killer world-wide with 1.8mill fatalities out of 10mill diagnosed patients in 2019. TB is an opportunistic mycobacterium residing dormant in human cells that may develop into potentially deadly lung infections at a given point. Multidrug resistant TB is practically incurable by standard first-line treatment, and an increasing number of infections are becoming resistant to all available treatments.

AdjuTec addresses this global problem by developing a class of compounds inhibiting the DNA function of resistant TB bacteria
AdjuTec is in discussions with EMA and FDA to optimize the regulatory strategy moving forward. All products are covered by patents in the major markets.
APC277 is an investigational product in early preclinical development for treatment of resistant tuberculosis.

APC148 is the AdjuTec lead BLI product that will be used as an adjuvant together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in preclinical development, aiming at an IND/CTA application in 2023.

APC247 is a broad-spectrum BLI product that will be used as an adjuvant also together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in early preclinical development.
Projects
AdjuTec First-in-class Technology
metallo-β-lactamase resistance breaker APC148 destroys vital bacterial carbapenem-resistance mechanisms (MBL) and prevents the bacteria from defending itself from the antibiotic.